Академический Документы
Профессиональный Документы
Культура Документы
http://www.invokanahcp.com/safety-information/safety-and-tolerability-
profile?utm_source=google&utm_medium=cpc&utm_campaign=Invokana+HCP&utm_term=canagliflozin%20side%20effects&utm_content=Side+Effe
cts+-+Exact|mkwid|suZUJen2m|pcrid|24016786155
Canagliflozin
Drug Interactions:
1.UGT Inducers (Rifampin, Phenytoin, Phenobarbitol,
Ritonavir)- Decreased canagliflozin, consider
increasing dose of canagliflozin
2.Digoxin- Increased digoxin concentration, monitor
levels
Pregnancy Category C
Do Not Use: GFR <30mL/min, end stage renal
disease, or patients on dialysis
SGLT-2 Inhibitor-Canagliflozin
Pipeline:
1.Empagliglozin (Eli Lilly/Behringer)
2.Dapagliflozin (AstraZeneca)
3.Remogliflozin Etabonate (GlaxoSmithKline)
4.Sergliflozin Etabonate (GlaxoSmithKline)
5.Tofoglitazone (Roche & Chugal)
Comparing Agents
Medication Average A1C Hypoglycemic Weight
lowering Agent Gain/Loss
Metformin 1.5% No Loss
Berkrot, Bill. "Johnson & Johnson Diabetes Drug Tops Older Therapies in Studies."
Reuters. Thomson Reuters, 09 June 2012. Web. 02 Apr. 2013.
"Canagliflozin Provided Substantial and Sustained Glycemic Improvements as
Monotherapy and in Add-On Combinations in Adults with Type 2 Diabetes in Five
Phase 3 Studies." Johnson & Johnson. Jansen Research & Development, 09 June
2012. Web. 02 Apr. 2013.
Clarke, Toni. "FDA Approves Johnson & Johnson Diabetes Drug, Canagliflozin."
Reuters. Thomson Reuters, 29 Mar. 2013. Web. 01 Apr. 2013.
"Diabetes Treatment, Part 2: Oral Agents for Glycemic Management." Clinical
Diabetes. N.p., Oct. 2007. Web. 12 Apr. 2013.
FDA Approves Invokana to Treat Type 2 Diabetes. N.p., n.d. Web. 01 Apr. 2013
"Invokana." INVOKANA™ (Canagliflozin) Treatment for Type 2 Diabetes. N.p., n.d.
Web. 12 Apr. 2013
Nainggolan, Lisa. "FDA Approves Canagliflozin, a First-in-Class Diabetes Drug."
Medscape Log In. N.p., 29 Mar. 2013. Web. 01 Apr. 2013.